Bumetanide

Research use only, not for human use.

An inhibitor of Na(+)-K(+)-2Cl(-) co-transporter (NKCC) with an IC50 of 0.6 uM.

An inhibitor of Na(+)-K(+)-2Cl(-) co-transporter (NKCC) with an IC50 of 0.6 uM; decreases internal chloride concentration in neurons; inhibits ouabain-resistant 86Rb(K+) influx with IC50 of 0.1, 5.0, and 0.05 microM for J774.2, CT2 and J7H1 macrophages, respectively; a loop diuretic most often used to treat heart failure.Heart Failure Withdrawn.

——

Animal Model:Normotensive Sprague-Dawley rats (250-300 g)Dosage:7.6 mg/kg, 15.2 mg/kg, 30.4 mg/kg Administration:Intravenous injection Result:Reduced the middle cerebral artery occlusion (MCAO)-induced decrease in ADC values in all four ipsilateral regions (L1-L4).Animal Model:Male Sprague-Dawley rats (220-300 g)Dosage:2 mg/kg, 8 mg/kg, 20 mg/kg (Pharmacokinetic Analysis) Administration:Intravenous administration Result:T1/2 (21.4 min, 53.8 min and 137 min for 2 mg/kg, 8 mg/kg and 20 mg/kg, respectively )

Ro 10-6338 | PF-1593

Membrane Transporter/Ion Channel

NKCC

Na-K-Clcotransporter

Cardiovascular Disease

——

28395-03-1

364.4161

C17H20N2O5S

>98% (HPLC)

10 mM in DMSO

O=C(O)C1=CC(S(=O)(N)=O)=C(OC2=CC=CC=C2)C(NCCCC)=C1

Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-

(-20℃)

With Ice Pack

≥ 2 years